Profile data is unavailable for this security.
About the company
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
- Revenue in USD (TTM)84.30m
- Net income in USD-104.32m
- Incorporated2004
- Employees204.00
- LocationUrogen Pharma Ltd9 Ha'ta'asiya StRA'ANANA 4365007IsraelISR
- Phone+972 97707601
- Websitehttps://www.urogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc | 0.00 | -168.82m | 653.24m | 107.00 | -- | -- | -- | -- | -3.26 | -3.26 | 0.00 | 2.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -38.47 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.30m | 662.50m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 664.96m | 344.00 | -- | 1.69 | -- | 7.67 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Mineralys Therapeutics Inc | 0.00 | -90.80m | 666.28m | 28.00 | -- | 2.03 | -- | -- | -2.18 | -2.18 | 0.00 | 6.61 | 0.00 | -- | -- | 0.00 | -27.78 | -- | -29.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| ACELYRIN Inc | 0.00 | -240.16m | 683.29m | 130.00 | -- | 1.06 | -- | -- | -2.59 | -2.59 | 0.00 | 6.52 | 0.00 | -- | -- | 0.00 | -48.23 | -- | -52.78 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Arrivent Biopharma Inc | -100.00bn | -100.00bn | 684.28m | 40.00 | -- | 2.15 | -- | -- | -- | -- | -- | 9.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 684.67m | 216.00 | -- | 4.24 | -- | 325.26 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Replimune Group Inc | 0.00 | -215.79m | 685.95m | 331.00 | -- | 1.65 | -- | -- | -3.24 | -3.24 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -38.05 | -29.08 | -40.71 | -30.56 | -- | -- | -- | -- | -- | -- | 0.1593 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
| Prime Medicine Inc | 591.00k | -204.50m | 694.98m | 234.00 | -- | 2.85 | -- | 1,175.94 | -2.17 | -2.17 | 0.0062 | 2.03 | 0.0019 | -- | -- | 2,525.64 | -65.09 | -- | -70.51 | -- | -- | -- | -34,601.86 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Urogen Pharma Ltd | 84.30m | -104.32m | 697.42m | 204.00 | -- | -- | -- | 8.27 | -3.39 | -3.39 | 2.69 | -1.11 | 0.5378 | 1.39 | 6.33 | 425,767.70 | -66.54 | -77.21 | -79.65 | -91.06 | 89.53 | 88.80 | -123.74 | -268.92 | 7.20 | -7.05 | 1.70 | -- | 28.52 | 136.08 | 6.87 | -- | -19.10 | -- |
| Phathom Pharmaceuticals Inc | 2.59m | -246.63m | 710.03m | 452.00 | -- | -- | -- | 273.72 | -4.41 | -4.41 | 0.047 | -2.54 | 0.0104 | -- | -- | 5,738.94 | -98.55 | -83.26 | -111.44 | -93.77 | 77.14 | -- | -9,507.71 | -135,982.00 | 7.80 | -5.29 | 1.46 | -- | -- | -- | -1.96 | -- | -- | -- |
| Arbutus Biopharma Corp | 12.99m | -74.39m | 722.79m | 73.00 | -- | 6.02 | -- | 55.66 | -0.4393 | -0.4393 | 0.0766 | 0.6362 | 0.0761 | -- | 5.41 | 177,890.40 | -43.56 | -52.62 | -50.25 | -58.11 | -- | -- | -572.81 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Savara Inc | 0.00 | -64.49m | 733.33m | 37.00 | -- | 5.06 | -- | -- | -0.3848 | -0.3848 | 0.00 | 0.8819 | 0.00 | -- | -- | 0.00 | -44.84 | -36.86 | -47.26 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.1782 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Scholar Rock Holding Corp | 0.00 | -183.26m | 733.74m | 150.00 | -- | 4.01 | -- | -- | -2.09 | -2.09 | 0.00 | 2.29 | 0.00 | -- | -- | 0.00 | -62.98 | -38.14 | -70.72 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2151 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| Zymeworks Inc | 50.46m | -125.97m | 733.92m | 275.00 | -- | 1.69 | -- | 14.54 | -1.79 | -1.79 | 0.7086 | 6.15 | 0.0874 | -- | 1.03 | 185,529.40 | -21.82 | -22.58 | -24.45 | -26.90 | -- | -- | -249.63 | -91.17 | -- | -- | 0.0002 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| SS Innovations International Inc | 11.22m | -22.75m | 734.18m | 239.00 | -- | 54.24 | -- | 65.44 | -0.1372 | -0.1372 | 0.0698 | 0.0793 | 0.6146 | -- | 2.43 | 46,943.05 | -124.63 | -161.38 | -289.30 | -449.76 | 11.08 | -79.79 | -202.80 | -495.77 | 0.8699 | -57.41 | 0.3901 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
Data as of Jul 23 2024. Currency figures normalised to Urogen Pharma Ltd's reporting currency: US Dollar USD
53.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Mar 2024 | 3.26m | 7.92% |
| RA Capital Management LPas of 31 Mar 2024 | 3.08m | 7.50% |
| Great Point Partners LLCas of 30 Jun 2024 | 2.91m | 7.07% |
| Point72 Asset Management LPas of 14 Jun 2024 | 2.57m | 6.25% |
| Menora Mivtachim Insurance Ltd.as of 31 Mar 2024 | 2.30m | 5.60% |
| Menora Mivtachim Provident Funds Ltd.as of 31 Dec 2023 | 2.03m | 4.94% |
| TD Securities (USA) LLCas of 31 Mar 2024 | 1.63m | 3.96% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.54m | 3.74% |
| Adage Capital Management LPas of 31 Mar 2024 | 1.30m | 3.16% |
| Credit Suisse Asset Management (Schweiz) AGas of 31 Mar 2024 | 1.20m | 2.92% |
More ▼
Data from 31 Mar 2024 - 08 Jul 2024Source: FactSet Research Systems Inc.
